combined paediatric vaccines for national immunization programmes
Download
Skip this Video
Download Presentation
Combined paediatric vaccines for national immunization programmes

Loading in 2 Seconds...

play fullscreen
1 / 42

Combined paediatric vaccines for national immunization programmes - PowerPoint PPT Presentation


  • 107 Views
  • Uploaded on

Combined paediatric vaccines for national immunization programmes. Francis E. André Vice-President and senior Medical Director GlaxoSmithKline , Rixensart, Belgium. Current shifts in pediatric immunization. Replacement of DTPw by DTPa Introduction of universal hepatitis B vaccination

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Combined paediatric vaccines for national immunization programmes' - gomer


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
combined paediatric vaccines for national immunization programmes

Combined paediatric vaccines for national immunization programmes

Francis E. André

Vice-President and senior Medical Director

GlaxoSmithKline, Rixensart, Belgium

current shifts in pediatric immunization
Current shifts in pediatric immunization
  • Replacement of DTPw by DTPa
  • Introduction of universal hepatitis B vaccination
  • Introduction of universal Hib vaccination
  • Switch from OPV to IPV
slide4

DTPa

DTPa / Hib

DTPa - HBV

DTPa - HBV/ Hib

DTPa - IPV

DTPa - IPV / Hib

DTPa - HBV - IPV /Hib

DTPa - HBV - IPV

SB DTPa-based pediatric combinations

DTP : Diphtheria/ Tetanus/ PT, FHA, Pertactin

HBV : Recombinant HBsAg

IPV : Inactivated enhanced-potency polio vaccine

Hib : Lyophilized PRP-T conjugate

slide5

DTPa

DTPa / Hib

DTPa - HBV

DTPa - HBV/ Hib

DTPa - IPV

DTPa - IPV / Hib

SB DTPa-based pediatric combinations

DTP : Diphtheria/ Tetanus/ PT, FHA, Pertactin

HBV : Recombinant HBsAg

IPV : Inactivated enhanced-potency polio vaccine

Hib : Lyophilized PRP-T conjugate

DTPa - HBV - IPV /Hib

Infanrix hexa

DTPa - HBV - IPV

Infanrix penta

slide6

Infanrix penta

DTPa components

D: 25 Lf PT: 25 mcg

T: 10 Lf FHA: 25 mcg

PRN: 8 mcg

Polio components

Polio 1: 40 DU

Polio 2: 8 DU

Polio 3: 32 DU

Hepatitis B component

HBsAg: 10 mcg

Excipients: Alum salts as adjuvant 2-Phenoxyethanol as antiseptic

slide7

Infanrix penta and Infanrix hexa

Hib component

PRP: 10 mcg

conjugated to TT

DTPa components

D: 25 Lf PT: 25 mcg

T: 10 Lf FHA: 25 mcg

PRN: 8 mcg

Polio components

Polio 1: 40 DU

Polio 2: 8 DU

Polio 3: 32 DU

Hepatitis B component

HBsAg: 10 mcg

Excipients: Alum salts as adjuvant 2-Phenoxyethanol as antiseptic

potentially deleterious interactions between vaccine components

Antigens

Adjuvant(s)

Preservative(s)

pH

Contaminants

Stabilizer(s)

Excipient(s)

Potentially deleterious interactions between vaccine components

Possible adverse consequences

  • Reduced immunogenicity
  • Increased reactogenicity
  • Shortened shelf life
  • Complicated manufacture
infanrix penta and infanrix hexa key objectives of clinical development
Infanrix penta and Infanrix hexa:Key objectives of clinical development

Demonstration of

  • safety and acceptable reactogenicity
  • immunogenicity in various schedules
  • persistence of antibodies up to the booster dose
  • protective efficacy of each vaccine component
  • lot-to-lot consistency
infanrix penta and infanrix hexa integrated clinical trial programme
Infanrix penta and Infanrix hexa:Integrated clinical trial programme
  • Common inclusion and exclusion criteria
  • Common reactogenicity assessment
  • Common serological assays
  • Randomized controlled trials: predefined statistical criteria to demonstrate non-inferiority vs. licensed vaccines
infanrix penta primary immunization trials
Infanrix penta: primary immunization trials

* a dose of HBV was given at birth

slide12

Infanrix hexa: primary immunization trials

* one study group received a dose of HBV at birth

slide13

Infanrix penta + Hib vs. separate administration of antigens: study design

Group 2 mo 4 mo 6 mo

DTPa-HepB-IPV + Hib 

DTPa-HepB-IPV + Hib  DTPa-HepB + Hib + OPV

DTPa-HepB + IPV + Hib 

DTPa + HepB + Hib + OPV 

Combined

IPV-OPV

IPV

Separate

(OPV)

All groups N = 100 enrolled

Study 015: Ward, USA

immunogenicity of d t and hbsag

Combined (N=89-90)

Separate (N=77-78)

Immunogenicity of D, T and HBsAg

% Seroprotection

GMTs: 1.3 0.8 3.7 2.3 1661 805

anti-D, anti-T: IU/ml; anti-HBs: mIU/ml Study 015: Ward, USA

immunogenicity of pt fha and prn

Combined (N=91)

Separate (N=77-78)

Immunogenicity of PT, FHA and PRN

% Vaccine Response

GMTs: 97 47 119 153 150 109

anti-PT, anti-FHA, anti-PRN: EL.U/ml Study 015: Ward, USA

immunogenicity of polio types 1 2 and 3

Combined (N=86)

Separate OPV (N=73)

Immunogenicity of Polio types 1, 2, and 3

% Seroprotection

GMTs: 415 819 514 1262 1729 453

Study 015: Ward, USA

slide17

Immunogenicity of Polio types 1, 2, and 3

Combined (N=86)

Separate IPV (N=77)

% Seroprotection

GMTs: 415 213 514 329 1729 432

Study 015: Ward, USA

study 015 local reactions

o o o

Study 015 - Local Reactions

Group 1 = Combined

Group 4 = Separate + OPV

OPV

DTPa-HepB-IPV

Hib

DTPa

Hib

HepB

2 injections

3 injections

study 015 incidence of redness by dose
Study 015: Incidence (%) of redness by dose

(N = 84 - 100 per dose)

4-day follow-up period

study 015 incidence of swelling by dose
Study 015: Incidence (%) of swelling by dose

(N = 84 - 100 per dose)

4-day follow-up period

study 015 incidence of pain by dose
Study 015: Incidence (%) of pain by dose

(N = 84 - 100 per dose)

4-day follow-up period

study 015 incidence of solicited general symptoms per subject
Study 015: Incidence (%) of solicited general symptoms per subject

4-day follow-up period over the full vaccination course

study 015 incidence of grade 3 solicited general symptoms per subject
Study 015: Incidence (%) of “grade 3” solicited general symptoms per subject

4-day follow-up period over the full vaccination course

slide24

Infanrix hexa vs. separate administration of antigens (standard of care)

Group N Vaccine(s) # injections

Combined 134 DTPa-HBV-IPV/Hib 1

Separate 134 DTPa + HBV + Hib + OPV 3

  • Open, randomized, multicenter
  • Schedule: 2, 4, 6 months
  • Study 001: Blatter, USA
immunogenicity of d t and hbsag1

Combined (N=134)

Separate (N=134)

Immunogenicity of D, T and HBsAg

% Seroprotection

GMTs: 1.43 1.01 1.98 1.49 1240 934

anti-D, anti-T: IU/ml; anti-HBs: mIU/ml Study 001, Blatter, USA

immunogenicity of pt fha and prn1

Combined (N=134)

Separate (N=134)

Immunogenicity of PT, FHA, and PRN

% Vaccine Response

GMTs: 67.4 41.8 288 303 168 137

anti-PT, anti-FHA, anti-PRN: EL.U/ml Study 001: Blatter, USA

immunogenicity of polio types 1 2 and 31

Combined (N=134)

Separate (N=134)

Immunogenicity of Polio types 1, 2, and 3

% Seroprotection

GMTs: 495 1278 507 1350 1275 368

Study 001: Blatter, USA

immunogenicity of hib anti prp antibodies

Combined (N=134)

Separate (N=134)

Immunogenicity of Hib: anti-PRP antibodies

100 %

96.9 %

84.0 %

91.8 %

% Seroprotection

GMCs: 2.65 5.52

Study 001: Blatter, USA

slide29

DTPa-HBV-IPV/Hib (N=134)

DTPa + HBV + Hib + OPV (N=134)

Study 001: reactogenicity

% subjects reporting the symptom(regardless of injection site)

Pain

Redness

Swelling

Fever

Grade 3

> 20 mm

> 20 mm

> 39.5 °C

slide30

DTPa-HBV-IPV/Hib (N =166)

DTPw-IPV/Hib (Pentacoq TM) + HBV (Engerix TM) (N =82)

Pain

Redness

Swelling

Fever

Grade 3

> 20 mm

> 20 mm

Reactogenicity of Infanrix hexa vs. whole-cell pertussis - containing combination

% subjects reporting the symptom(regardless of injection site)

> 39.5 °C

Study 025: Cohen, France, schedule 2-3-4

slide31
Infanrix hexa: seroprotection rates for antigens with established surrogate markers of protection(all studies, all schedules)

* by ELISA

infanrix hexa d t pa hepb ipv
Infanrix hexa: D, T, Pa, HepB, IPV
  • Non-inferiority of Infanrix hexa post-primary vaccination as compared to licensed vaccines
    • DTPa-IPV/Hib
    • DTPw-IPV/Hib
    • Separate administration of DTPa, HepB, Hib and OPV
  • Similar distribution of antibody titres (Reverse Cumulative Distribution Curves - RCCs)
slide33

Anti-PT antibody titres following administration of DTPa-HBV-IPV/Hib and of DTPa (Infanrix™) vaccine

Household contact study*

Household contact study **

DTPa-HBV-IPV/Hib

DTPa-HBV-IPV/Hib

Percentage of subjects

Anti-PT antibody titre (EU/ml)

RCCs generated for lots that induced the highest (*) and lowest (**) antibody response

Study 048, PI: Heininger, Germany, schedule 3-4-5

hib immunogenicity
Hib immunogenicity

Anti-PRP antibody titres are lower when Hib vaccines are combined with DTPa-based vaccines as compared to the separate injection of the vaccines

slide36

Infanrix hexa: Hib

In all clinical trials, regardless of vaccination schedule, 96 % of subjects achieved concentrations  0.15 µg/ml

Non-inferiority of Infanrix hexa as compared to licensed DTPa-IPV/Hib vaccine

Identical functional capacity of anti-PRP antibodies induced by Infanrix hexa and by licensed Hib vaccines

Effective induction of immune memory

Proven field effectiveness of DTPa/Hib andDTPa-IPV/Hib under conditions of routine use

slide37

Infanrix hexa as a 4th dose: reactogenicity

  • Subjects primed with 3 doses of Infanrix hexa(study 039)
  • Randomised at 12-18 months to 3 booster groups
  • N
    • DTPa-IPV/Hib 163
    • DTPa-IPV/Hib + HepB168
    • Infanrix hexa 544

Study 058: Zepp, Germany

slide38

DTPa-IPV/Hib (N=163)

DTPa-IPV/Hib + HBV (N=168)

Infanrix hexa (N=544)

Incidence of solicited symptomsfollowing 3 different boosters

% of subjects with a symptom

slide39

DTPa-IPV/Hib (N=163)

DTPa-IPV/Hib + HBV (N=168)

Infanrix hexa (N=544)

= Grade 3; fever > 39.5°C

Incidence of solicited symptomsfollowing 3 different boosters

% of subjects with a symptom

slide40

DTPa-IPV/Hib (N=163)

DTPa-IPV/Hib + HBV (N=168)

Infanrix hexa (N=544)

Incidence of solicited symptomsfollowing 3 different boosters

60

50

40

% of subjects with a symptom

30

20

10

0

Irritability

Sleepiness

Loss of appetite

in all clinical trials no cases reported of
In all clinical trials,no cases reported of
  • Hypotonic hyporesponsiveness
  • Encephalopathy
  • Anaphylaxis

Infanrix penta: 23 439 doses Infanrix hexa: 15 920 doses

slide42

Infanrix penta and Infanrix hexa: conclusions

Protective efficacy not affected by combination of antigens

Tolerability of primary and booster doses in line with that

of other licensed vaccines

Reduced number of injections

Make room for new (pneumococcal, meningococcal) vaccines

Add value to current standard of medical care

ad